Discover
TPST
Tempest Therapeutics, Inc.
1.11
2 x 0.81
2 x 1.42
bid
ask
+
0.00
0.00%
2 @ 05:05 AM
1.11 +0.00 (0.00%)
| Ytd | -61.32% | |
| 1y | -84.43% |
1.09
day range
1.13
1.02
52 week range
12.23
| Open | 1.09 | Prev Close | 1.11 | Low | 1.09 | High | 1.13 | Mkt Cap | 17.74M |
| Vol | 43.45K | Avg Vol | 194.38K | EPS | -5.70 | P/E | N/A | Forward P/E | -0.61 |
| Beta | -2.78 | Short Ratio | 0.39 | Inst. Own | 23.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 1.58 | 200-d Avg | 4.10 | 1yr Est | 18.75 |
| Income Statement | |||
| Operating Expenses | 27.72M | ||
| Research and Development Expense | 114.00K | ||
| Selling, General and Administrative Expense | 5.43M | ||
| Operating Income | -27.72M | ||
| Net Income | -27.70M | ||
| Net Income Common Stock | -27.70M | ||
| Net Income Common Stock (USD) | -27.70M | ||
| Consolidated Income | -27.70M | ||
| Earnings per Basic Share | -2.53 | ||
| Earnings per Basic Share (USD) | -2.53 | ||
| Earnings per Diluted Share | -2.53 | ||
| Earning Before Interest & Taxes (EBIT) | -27.70M | ||
| Earning Before Interest & Taxes (USD) | -27.70M | ||
| Weighted Average Shares | 10.93M | ||
| Weighted Average Shares Diluted | 10.93M | ||
| Balance Sheet | |||
| Cash and Equivalents | 1.81M | ||
| Cash and Equivalents (USD) | 1.81M | ||
| Current Assets | 2.45M | ||
| Property, Plant & Equipment Net | 7.79M | ||
| Total Assets | 10.75M | ||
| Debt Current | 1.24M | ||
| Total Debt | 7.85M | ||
| Current Liabilities | 3.31M | ||
| Debt Non-Current | 6.62M | ||
| Total Liabilities | 9.93M | ||
| Accumulated Retained Earnings (Deficit) | -270.07M | ||
| Shareholders Equity | 822.00K | ||
| Shareholders Equity (USD) | 822.00K | ||
| Assets Non-Current | 8.30M | ||
| Total Debt (USD) | 7.85M | ||
| Liabilities Non-Current | 6.62M | ||
| Trade and Non-Trade Payables | 585.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 352.00K | ||
| Net Cash Flow from Financing | 1.70M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -5.90M | ||
| Issuance (Purchase) of Equity Shares | 1.70M | ||
| Net Cash Flow from Operations | -7.60M | ||
| Share Based Compensation | 226.00K | ||